These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 30919552)

  • 1. Clinical implications of the genetics of sporadic colorectal cancer.
    Fischer J; Walker LC; Robinson BA; Frizelle FA; Church JM; Eglinton TW
    ANZ J Surg; 2019 Oct; 89(10):1224-1229. PubMed ID: 30919552
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of Chilean patients with sporadic colorectal cancer according to the three main carcinogenic pathways: Microsatellite instability, CpG island methylator phenotype and Chromosomal instability.
    Wielandt AM; Hurtado C; Moreno C M; Villarroel C; Castro M; Estay M; Simian D; Martinez M; Vial MT; Kronberg U; López-Köstner F
    Tumour Biol; 2020 Jul; 42(7):1010428320938492. PubMed ID: 32635826
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part I-Colorectal Cancer: Microsatellite Instability, Testing, and Clinical Implications.
    Marginean EC; Melosky B
    Arch Pathol Lab Med; 2018 Jan; 142(1):17-25. PubMed ID: 29144791
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetics and Genetic Biomarkers in Sporadic Colorectal Cancer.
    Carethers JM; Jung BH
    Gastroenterology; 2015 Oct; 149(5):1177-1190.e3. PubMed ID: 26216840
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinicopathologic and molecular characteristics of synchronous colorectal cancers: heterogeneity of clinical outcome depending on microsatellite instability status of individual tumors.
    Bae JM; Cho NY; Kim TY; Kang GH
    Dis Colon Rectum; 2012 Feb; 55(2):181-90. PubMed ID: 22228162
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinicopathological features of CpG island methylator phenotype-positive colorectal cancer and its adverse prognosis in relation to KRAS/BRAF mutation.
    Lee S; Cho NY; Choi M; Yoo EJ; Kim JH; Kang GH
    Pathol Int; 2008 Feb; 58(2):104-13. PubMed ID: 18199160
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Possible role of Cdx2 in the serrated pathway of colorectal cancer characterized by BRAF mutation, high-level CpG Island methylator phenotype and mismatch repair-deficiency.
    Dawson H; Galván JA; Helbling M; Muller DE; Karamitopoulou E; Koelzer VH; Economou M; Hammer C; Lugli A; Zlobec I
    Int J Cancer; 2014 May; 134(10):2342-51. PubMed ID: 24166180
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel classification of colorectal tumors based on microsatellite instability, the CpG island methylator phenotype and chromosomal instability: implications for prognosis.
    Simons CC; Hughes LA; Smits KM; Khalid-de Bakker CA; de Bruïne AP; Carvalho B; Meijer GA; Schouten LJ; van den Brandt PA; Weijenberg MP; van Engeland M
    Ann Oncol; 2013 Aug; 24(8):2048-56. PubMed ID: 23532114
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Distinct features between MLH1-methylated and unmethylated colorectal carcinomas with the CpG island methylator phenotype: implications in the serrated neoplasia pathway.
    Kim JH; Bae JM; Cho NY; Kang GH
    Oncotarget; 2016 Mar; 7(12):14095-111. PubMed ID: 26883113
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular pathways in colorectal cancer.
    Al-Sohaily S; Biankin A; Leong R; Kohonen-Corish M; Warusavitarne J
    J Gastroenterol Hepatol; 2012 Sep; 27(9):1423-31. PubMed ID: 22694276
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Methylator phenotype in colorectal cancer: A prognostic factor or not?
    Gallois C; Laurent-Puig P; Taieb J
    Crit Rev Oncol Hematol; 2016 Mar; 99():74-80. PubMed ID: 26702883
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High microsatellite instability (MSI-H) colorectal carcinoma: a brief review of predictive biomarkers in the era of personalized medicine.
    Gatalica Z; Vranic S; Xiu J; Swensen J; Reddy S
    Fam Cancer; 2016 Jul; 15(3):405-12. PubMed ID: 26875156
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and molecular characterisation of hereditary and sporadic metastatic colorectal cancers harbouring microsatellite instability/DNA mismatch repair deficiency.
    Cohen R; Buhard O; Cervera P; Hain E; Dumont S; Bardier A; Bachet JB; Gornet JM; Lopez-Trabada D; Dumont S; Kaci R; Bertheau P; Renaud F; Bibeau F; Parc Y; Vernerey D; Duval A; Svrcek M; André T
    Eur J Cancer; 2017 Nov; 86():266-274. PubMed ID: 29055842
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relevance, pathogenesis, and testing algorithm for mismatch repair-defective colorectal carcinomas: a report of the association for molecular pathology.
    Funkhouser WK; Lubin IM; Monzon FA; Zehnbauer BA; Evans JP; Ogino S; Nowak JA
    J Mol Diagn; 2012; 14(2):91-103. PubMed ID: 22260991
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A prognostic CpG score derived from epigenome-wide profiling of tumor tissue was independently associated with colorectal cancer survival.
    Jia M; Zhang Y; Jansen L; Walter V; Edelmann D; Gündert M; Tagscherer KE; Roth W; Bewerunge-Hudler M; Herpel E; Kloor M; Ulrich A; Burwinkel B; Bläker H; Chang-Claude J; Brenner H; Hoffmeister M
    Clin Epigenetics; 2019 Jul; 11(1):109. PubMed ID: 31340858
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Colorectal cancer: epigenetic alterations and their clinical implications.
    Puccini A; Berger MD; Naseem M; Tokunaga R; Battaglin F; Cao S; Hanna DL; McSkane M; Soni S; Zhang W; Lenz HJ
    Biochim Biophys Acta Rev Cancer; 2017 Dec; 1868(2):439-448. PubMed ID: 28939182
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Annexin A10 expression correlates with serrated pathway features in colorectal carcinoma with microsatellite instability.
    Kim JH; Rhee YY; Kim KJ; Cho NY; Lee HS; Kang GH
    APMIS; 2014 Dec; 122(12):1187-95. PubMed ID: 24909058
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BRAF-Mutated Colorectal Cancer: What Is the Optimal Strategy for Treatment?
    Cohen R; Cervera P; Svrcek M; Pellat A; Dreyer C; de Gramont A; André T
    Curr Treat Options Oncol; 2017 Feb; 18(2):9. PubMed ID: 28214977
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular pathways and cellular metabolism in colorectal cancer.
    Hagland HR; Berg M; Jolma IW; Carlsen A; Søreide K
    Dig Surg; 2013; 30(1):12-25. PubMed ID: 23595116
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of Tumor Sequencing as a Replacement for Lynch Syndrome Screening and Current Molecular Tests for Patients With Colorectal Cancer.
    Hampel H; Pearlman R; Beightol M; Zhao W; Jones D; Frankel WL; Goodfellow PJ; Yilmaz A; Miller K; Bacher J; Jacobson A; Paskett E; Shields PG; Goldberg RM; de la Chapelle A; Shirts BH; Pritchard CC;
    JAMA Oncol; 2018 Jun; 4(6):806-813. PubMed ID: 29596542
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.